A proprietary intelligence layer for rare disease.
A platform that structures clinical, phenotypic and real-world data into decision-useful intelligence for developers, investigators, regulators and access teams.
Rare disease data is scattered by design.
Clinical signals sit in unstructured notes. Cohorts are undercounted. Investigators lack visibility to peers. Real-world evidence remains anecdotal. The result: therapies that struggle to find patients and patients who struggle to be seen.
An intelligence platform, not a diagnostic tool.
Our platform structures data to help clinicians and developers make better decisions. It supports diagnostic pathways — it does not replace them.
Human clinical judgment. AI-enabled infrastructure.
Rare disease requires human clinical judgment, specialist interpretation and local medical credibility. AI-enabled infrastructure organizes, compares and prioritizes complex information — always in service of qualified clinicians, investigators and program teams.
Structured clinical data lake
Consented, governed integration of clinical and phenotypic data.
Phenotype mapping
HPO-aligned patterning and signal detection across rare presentations.
Neural modeling
Models trained on curated cohorts to surface potential candidates.
Cohort identification
Stratification of populations aligned to therapeutic mechanism.
Investigator & site mapping
Discovery of centers and specialists with real cohort access.
Real-world evidence
Longitudinal analysis to inform access and post-market strategy.
- 01
Ingest
Consented data streams from partner institutions.
- 02
Structure
Standardized vocabularies, HPO alignment, provenance.
- 03
Model
Phenotypic pattern detection under clinical governance.
- 04
Deliver
Signals returned to clinicians and program teams for review.
Shortening diagnostic journeys
Surface candidate presentations for investigator review.
Cohort discovery for trials
Identify feasible populations by geography and phenotype.
Access & post-market intelligence
Longitudinal evidence to support reimbursement and continuity.
Consent, governance, auditability and clinical oversight are prerequisites — not features. We publish our data governance framework.
Building rare disease infrastructure, together.
If you are advancing a therapy, investing in the space, running a clinical program or coordinating patient identification — start a conversation with us.